Charles Schwab Investment Management Inc. Buys 9,328 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Charles Schwab Investment Management Inc. lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 1.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 956,362 shares of the company’s stock after purchasing an additional 9,328 shares during the period. Charles Schwab Investment Management Inc. owned 0.77% of Apellis Pharmaceuticals worth $27,581,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Assenagon Asset Management S.A. raised its stake in shares of Apellis Pharmaceuticals by 191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after purchasing an additional 1,409,707 shares in the last quarter. Fiera Capital Corp raised its stake in shares of Apellis Pharmaceuticals by 47.7% during the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock worth $53,750,000 after purchasing an additional 452,753 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Apellis Pharmaceuticals by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company’s stock worth $13,242,000 after purchasing an additional 22,273 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Apellis Pharmaceuticals by 337.3% during the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock worth $9,177,000 after purchasing an additional 190,420 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Apellis Pharmaceuticals by 42.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after acquiring an additional 39,931 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

APLS opened at $34.13 on Thursday. The firm has a market cap of $4.25 billion, a P/E ratio of -16.81 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $73.80. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The business’s fifty day moving average is $28.92 and its 200-day moving average is $35.15.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period last year, the company posted ($1.17) earnings per share. Sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at $3,623,000. This represents a 27.01 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Needham & Company LLC decreased their target price on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. UBS Group decreased their target price on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 target price on the stock. Mizuho decreased their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. Finally, HC Wainwright decreased their target price on Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $49.94.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).